Back Funds overview

Candriam | Candriam Oncology Impact Acc

The fund will invest in shares of companies operating in the field of oncology (study, diagnosis, treatment, etc. of cancer) whose registered offices and/or principal activities are in the whole world. The fund seeks to achieve capital growth by investing in the principal assets traded, outperform the benchmark index and thus have a positive social long term impact, by selecting companies that take on certain societal challenges and that deploy resources in the fight against cancer.
Quote
Quote
€261,53
Quote date
18-05-2026
Performance in EUR
Date
18-05-2026
This year
-4,34%
1 week
-0,26%
1 month
-5,51%
3 months
-5,94%
6 months
-2,01%
1 year
20,89%
3 years (annualised)
2,54%
5 years (annualised)
3,41%
Since start (annualised)
7,94%
Indicators
Standard deviation (3yr)
16,00%
Share ratio (3yr)
0,13
Beta (3yr)
1,14
Alpha (3yr)
1,87
Tracking error (3yr)
7,05
Top 10 holdings (31-10-2025)
Eli Lilly and Co
6,63 %
AstraZeneca PLC
4,28 %
Thermo Fisher Scientific Inc
3,41 %
Novartis AG Registered Shares
3,40 %
Intuitive Surgical Inc
3,28 %
Gilead Sciences Inc
3,24 %
AbbVie Inc
3,20 %
Danaher Corp
3,14 %
Amgen Inc
3,09 %
Regeneron Pharmaceuticals Inc
3,01 %
Fees
Entry fee
-->Tarievenkaart / Cost information sheet
Exit charges
-->Tarievenkaart / Cost information sheet
Estimated ongoing charges
1,11%
Dividend
Dividend paying
No
Characteristic
Asset Manager
Candriam
Asset class
Equities
Investment category
Equities - Global
Active/Passive
Active
Fund code
205143
Fund code fractional orders
-
Fund manager name
Linden Thomson|Servaas Michielssens
ISIN
LU1864483166
Sustainable Classification
Art. 9, impact investing
Sustainability Rating
Domicile
Luxembourg
Currency
EUR
Fund size (mio)
1.300,11 (15-05-2026)
Cut-off time
-
Execution date
-
Inception date
20-02-2019
Benchmark
MSCI World NR USD
Minimum investment amount
-
Assortiment
Self Directed Investing Plus, Investment advice